牛牛AI助理已提取核心訊息
Ryan Lewis Smith, a director and 10% owner of 180 Life Sciences Corp, has filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated March 7, 2024, indicates that Smith does not beneficially own any non-derivative or derivative securities of the company. The form, signed on March 11, 2024, is a standard disclosure for insiders of public companies, detailing their holdings and transactions in the company's stock. This filing is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934.
Ryan Lewis Smith, a director and 10% owner of 180 Life Sciences Corp, has filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated March 7, 2024, indicates that Smith does not beneficially own any non-derivative or derivative securities of the company. The form, signed on March 11, 2024, is a standard disclosure for insiders of public companies, detailing their holdings and transactions in the company's stock. This filing is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934.
180生命科學公司的董事兼10％所有者瑞安·劉易斯·史密斯已根據表格3的要求向美國證券交易委員會提交了初步的實益所有權聲明。該文件日期爲2024年3月7日，表明史密斯不以實益方式擁有該公司的任何非衍生或衍生證券。該表格於2024年3月11日簽署，是上市公司內部人士的標準披露內容，詳細說明了他們在公司股票中的持股和交易。該文件是1934年《證券交易法》第16（a）條規定的監管合規的一部分。
180生命科學公司的董事兼10％所有者瑞安·劉易斯·史密斯已根據表格3的要求向美國證券交易委員會提交了初步的實益所有權聲明。該文件日期爲2024年3月7日，表明史密斯不以實益方式擁有該公司的任何非衍生或衍生證券。該表格於2024年3月11日簽署，是上市公司內部人士的標準披露內容，詳細說明了他們在公司股票中的持股和交易。該文件是1934年《證券交易法》第16（a）條規定的監管合規的一部分。
有用
沒用